Outcome in gene expression profiling (GEP)–defined myeloma subgroups.

Kaplan-Meier plots of overall survival (OS) (left panel) and event-free survival (EFS) (right panel), dated from initiation of Total Therapy II, according to the GEP subgroups. Numbers in brackets indicate 95% confidence interval. Note that risk of relapse is significantly different between the groups. As expected, Group IV has the shortest EFS, Group III exhibits an intermediate risk, and Groups I and II, which are essentially the same, have the best prognosis. Although the OS is not currently significant, a trend similar to the EFS is evident. Groups I–IV are defined as above. The cumulative number of patients does not equal 221 due to removal of patients who had a diagnostic gene array but failed to start the protocol.